MED
Medifast, Inc.
MED has lower modeled downside risk, despite its lower overall score.
TSLA
Tesla, Inc.
TSLA has the edge over MED overall, supported by stronger fundamentals.
MED Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
MED's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
MED PE Valuation
MED has no meaningful PE right now: it lost money over the past year.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
MED Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MED's losses to shrink, with revenue holding steady.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TSLA, with profitability holding steady. However, they disagree widely on these estimates.
MED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.68 | -18500% |
| Q2 2026 | -$2.32 | -803% |
| Q1 2026 | -$1.82 | -$1.18 |
| Q4 2025 | -$1.70 | -995% |
| Q3 2025 | $0.02 | -97% |
| Q2 2025 | $0.33 | -88% |
| Q1 2025 | -$0.64 | -110% |
| Q4 2024 | $0.19 | -98% |
MED has swung to a loss: it lost $3.68 per share over the past year, after a profit the year before.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA has the edge over MED on earnings quality, reporting a profit while its opponent remains loss making.
MED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72M | -19% |
| Q2 2026 | $76.4M | -28% |
| Q1 2026 | $76M | -34% |
| Q4 2025 | $75.1M | -37% |
| Q3 2025 | $89.4M | -36% |
| Q2 2025 | $105.6M | -37% |
| Q1 2025 | $115.7M | -34% |
| Q4 2024 | $119M | -38% |
MED's revenue has slid since its 2022 peak: $72M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -27% | -22 points |
| Q2 2026 | -5.7% | -4.7 points |
| Q1 2026 | -4.3% | -3.2 points |
| Q4 2025 | -10% | -11 points |
| Q3 2025 | -4.6% | -6.1 points |
| Q2 2025 | -1% | +3.7 points |
| Q1 2025 | -1.1% | -5.6 points |
| Q4 2024 | 0.6% | -3.9 points |
MED's operating margin was −27% last quarter, down 22 points from the same quarter a year ago, near the bottom of its range since 2019.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA has the edge over MED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA has the edge over MED on profitability, with a higher operating margin.
MED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $728K | +$5.5M |
| Q1 2026 | -$836K | -144% |
| Q4 2025 | -$6.6M | +$603K |
| Q3 2025 | $10.8M | +40% |
| Q2 2025 | -$4.8M | -143% |
| Q1 2025 | $1.9M | -65% |
| Q4 2024 | -$7.2M | -176% |
MED's free cash flow has turned negative after years in the green: −$4M over the past year.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA has the edge over MED on cash generation, producing positive trailing cash flow while its opponent burns cash.
MED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +46K shares |
| 1 year | +1.7% | +190K shares |
| 3 years | +2.3% | +248K shares |
| 5 years | -5.1% | -604K shares |
| Available history | -7.7% | -936K shares |
MED has 11M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.6M |
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has the edge over MED on shareholder dilution, with a more favorable share count trend.
MED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -2,976.8x | Net Cash |
| Q3 2025 | -12.1x | Net Cash |
| Q2 2025 | -7.2x | Net Cash |
| Q1 2025 | -14.3x | Net Cash |
| Q4 2024 | -5.8x | Net Cash |
| Q3 2024 | -4.9x | Net Cash |
| Q2 2024 | -2.3x | Net Cash |
| Q1 2024 | -1.0x | Net Cash |
MED has more cash than debt.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has more cash than debt.
MED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 72.6 | Neutral |
MED's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
MED PE vs Consumer Cyclical Sector
| Metric | MED | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MED has no meaningful PE right now: it lost money over the past year.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
MED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 6% above |
| 20 week MA | $11.7 | 10% above |
| 50 week MA | $11.4 | 13% above |
| 100 week MA | $12.6 | 1.9% above |
| 200 week MA | $35.4 | 64% below |
MED has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 64% below its 200-week average.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA has the edge over MED on trend strength, trading above more of its moving averages.
MED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $196.7 | +82% |
| 2021 | $196.7 | $204.2 | +3.8% |
| 2022 | $204.2 | $117.1 | -43% |
| 2023 | $117.1 | $67.2 | -43% |
| 2024 | $67.2 | $17.6 | -74% |
| 2025 | $17.6 | $11.0 | -37% |
| 2026 YTD | $11.0 | $12.9 | +16% |
MED has the edge over TSLA on returns for 2026, with the stronger performance.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA's yearly returns have swung widely, from +669% in 2020 to −65% in 2022. It's down 16% so far in 2026.